Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease

American Journal of Medicine

Volumn 105, Issue 1 A, 1998, Pages 40S-47S

  Mancini, G B John ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BRADYKININ; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PERINDOPRIL; QUINAPRIL;

ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG EFFICACY; ENZYME INHIBITION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; PRIORITY JOURNAL; SECONDARY PREVENTION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0032490705     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00210-1     Document Type: Conference Paper

References (43)

1. Lonn E.M., Yusuf S., Jha P., et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 90:1994;2056-2069.
2. Rubanyi G.M. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol. 22:(suppl 4):1993;S1-S14.
3. Ludmer P.L., Selwyn A.P., Shook T.L., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 315:1986;1046-1051.
4. Werns S.W., Walton J.A., Hsia H.H., et al. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation. 79:1989;287-291.
5. Vita J.A., Treasure C.B., Nabel E.G., et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497.
6. von Lutterotti N., Caranzaro D.F., Sealey J.E., Laragh J.H. Renin is not synthesized by cardiac and extrarenal vascular tissues a review of experimental evidence . Circulation. 89:1994;458-470.
7. Dzau V.J., Re R. Tissue angiotensin system in cardiovascular medicine a paradigm shift? Circulation. 89:1994;493-498.
8. Dusting G.J., Macdonald P.S. Endogenous nitric oxide in cardiovascular disease and transplantation. Ann Med. 27:1995;395-406.
9. Naftilan A.J., Pratt R.E., Dzau V.J. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest. 83:1989;1419-1424.
10. Naftilan A.J., Pratt R.E., Eldridge C.S., Lin H.D., Dzau V.J. Angiotensin II induces c-fos expression in smooth muscle via transcriptional control. Hypertension. 13:1989;706-711.
11. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 74:1994;1141-1148.
12. Chobanian A.V., Haudenschild C.C., Nickerson C., Hope S. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 20:1992;473-477.
13. Aberg G., Ferrer P. Effects of captopril on atherosclerosis in Cynomolgus monkeys. J Cardiovas Pharmacol. 15:(suppl 5):1990;S65-S72.
14. Rolland P.H., Charpiot P., Friggi A., et al. Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini-pigs. Am J Cardiol. 71:1993;22E-27E.
15. Farber H.W., Center D.M., Rounds S., Danilov S.M. Components of the angiotensin system cause release of a neutrophil chemoattractant from cultured bovine and human endothelial cells. Eur Heart J. 11:(suppl B):1990;100-107.
16. Chobanian A.V., Alexander R.W. Exacerbation of atherosclerosis by hypertension potential mechanisms and clinical implications . Arch Intern Med. 156:1996;1952-1956.
17. Lüscher T.F., Boulanger C.M., Dohi Y., Yang Z. Endothelium-derived contracting factors. Hypertension. 19:1992;117-130.
18. James I.M., Dickenson E.J., Burgoyne W., et al. Treatment of hypertension with captopril preservation of regional blood flow and reduced platelet aggregation . J Human Hypertens. 2:1988;21-25.
19. Ridker P.M. An epidemiologic assessment of thrombotic risk factors for cardiovascular disease. Curr Opin Lipidol. 3:1992;285-290.
20. MacMahon S., Peto R., Cutler R., et al. Blood pressure, stroke, and coronary heart disease part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias . Lancet. 335:1990;765-774.
21. Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke and coronary heart disease part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context . Lancet. 335:1990;827-838.
22. Lüscher T.F., Noll G. Endothelial function as an end-point in interventional trials concepts, methods and current data . J Hyperten. 14:(suppl 2):1996;S111-S121.
23. Gilligan D.M., Badar D.M., Panza J.A., et al. Acute vascular effects of estrogen in postmenopausal women. Circulation. 90:1994;786-791.
24. Gilligan D.M., Badar D.M., Panza J.A., et al. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol. 75:1995;264-268.
25. Hirooka Y., Imaizumi T., Masaki H., et al. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension. 20:1992;175-180.
26. Panza J.A., Quyyumi A.A., Callahan T.S., Epstein S.E. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol. 21:1993;1145-1151.
27. Creager M.A., Roddy M.-A. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension. 24:1994;499-505.
28. Kiowski W., Linder L., Nuesch R., Martina B. Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension. 27:(part 1):1996;371-376.
29. Zhuo J.L., Froomes P., Casley D., et al. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation. 96:1997;174-182.
30. Rutherford J.D., Pfeffer M.A., Moyé L.A., et al. Effects of captopril on ischemic events after myocardial infarction results of the Survival and Ventricular Enlargement Trial . Circulation. 90:1994;1731-1738.
31. Yusuf S., Pepine C.J., Garces C., et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 340:1992;1173-1178.
32. Flather M.D., Kober L., Pfeffer M.A., et al. Meta-analysis of individual patient data from trials of long-term ACE-inhibitor treatment after acute myocardial infarction (SAVE, AIRE, and TRACE Studies). (Abstr.) Circulation. 98:1997;I-706.
33. Mancini G.B.J., Henry G.C., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease The TREND (Trial on Reversing ENdothelial Dysfunction) Study . Circulation. 94:1996;258-265.
34. Schlaifer J.D., Wargovich T.J., O'Neill B., et al. Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. Am J Cardiol. 80:1997;1594-1597.
35. Schlaifer J.D., Mancini G.B.J., O'Neill B.J., et al. Influence of smoking status on angiotensin-converting enzyme inhibition-related improvement in coronary endothelial function. (Abstr.) Eur Heart J. 18:1997;15.
36. Pitt B., Pepine C., O'Neill B., et al. Modulation of ACE inhibitor efficacy on coronary endothelial dysfunction by low density lipoprotein cholesterol. (Abstr.) J Am Coll Cardiol. 29:1997;70A.
37. Pepine C.J. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol. 27:1996;1048-1052.
38. Pepine C.J. Potential role of angiotensin-converting enzyme inhibition in myocardial ischemia and current clinical trials. Clin Cardiol. 20:(suppl II):1997;II-58-II-64.
39. Lees R.S., Pitt B., Chan R.C., et al. Baseline clinical and angiographic data in the Quinapril Ischemic Event (QUIET) Trial. Am J Cardiol. 78:1996;1011-1016.
40. Cashin-Hemphill L., Dinsmore R.E., Chan R.C., et al. Atherosclerosis progression in subjects with and without post-angioplasty restenosis in QUIET. (Abstr.) J Am Coll Cardiol. 29:1997;418A.
41. Cashin-Hemphill L., Dinsmore R.E., Chan R.C., et al. LDL cholesterol and angiographic progression in the QUIET Trial. (Abstr.) J Am Coll Cardiol. 29:1997;85A.
42. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
43. Anderson T.J., Meredith I.T., Yeung A.C., et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:1995;488-493.